UroGen Pharma Says FDA Approves Plan For Rolling NDA Submission For UGN-102 From January 2024

Biotech company UroGen Pharma Ltd. (URGN) announced Tuesday that it has reached agreement with the U.S. Food and Drug Administration (FDA) on plans for submission of a New Drug Application (NDA) for UGN-102 (mitomycin) for intravesical solution.

Related Keywords

,Drug Administration ,Urogen Pharma Ltd ,Urogen Pharma ,New Drug Application ,Itomycin ,Olling Nda Submission ,Burgn ,Ugn 102 ,Iotech Company Urogen Pharma ,Intravesical Solution ,